Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Verified date | June 2024 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV) in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have not been exposed to cancer immunotherapy (CIT) and for whom prior platinum-based therapy has failed. The study is comprised of two parts, as follows: A dose-finding part (Part 1, Phase Ib) will aim to identify the dose of atezolizumab SC to be tested in Part 2. A dose-confirmation part (Part 2, Phase III, randomized) will aim to confirm that the dose moved forward from Part 1 yields drug exposure that is comparable to that of atezolizumab IV.
Status | Active, not recruiting |
Enrollment | 438 |
Est. completion date | December 31, 2024 |
Est. primary completion date | April 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically documented locally advanced or metastatic NSCLC - Prior platinum-containing regimen or disease recurrence = 6 months since prior platinum-based adjuvant/neoadjuvant regimen. - Measurable disease as defined by RECIST v1.1 - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - Life expectancy =12 weeks - Adequate hematologic and end-organ function Additional Inclusion Criteria (Part 2 Only) • Availability of tissue and known epidermal growth factor receptor (EGFR) status Exclusion Criteria: - Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases - Uncontrolled or symptomatic hypercalcemia - Pregnancy or breastfeeding - Active or history of autoimmune disease or immune deficiency - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis - Severe infection = 4 weeks - Treatment with therapeutic oral or IV antibiotics = 2 weeks prior to study treatment - Significant cardiovascular disease - Prior allogeneic stem cell or solid organ transplantation - Treatment with a live, attenuated vaccine = 4 weeks - Treatment with systemic immunostimulatory agents = 4 weeks or 5 half-lives of the drug - Treatment with systemic immunosuppressive medication = 2 weeks Additional Exclusion Criteria (Part 2 Only) • Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive |
Country | Name | City | State |
---|---|---|---|
Argentina | Fundación CENIT para la Investigación en Neurociencias | Buenos Aires | |
Argentina | Centro Oncologico Riojano Integral (CORI) | La Rioja | |
Argentina | Consultorio Dr. Miguel Angel Escudero | Salta | |
Brazil | Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda | Ijui | RS |
Brazil | Hospital das Clinicas - UFRGS | Porto Alegre | RS |
Brazil | Hospital Nossa Senhora da Conceicao | Porto Alegre | RS |
Brazil | INCA 1- Instituto Nacional de Câncer X | Rio de Janeiro | RJ |
Brazil | Instituto do Cancer do Estado de Sao Paulo - ICESP | Sao Paulo | SP |
Chile | Bradford Hill Centro de Investigaciones Clinicas | Recoleta | |
Chile | James Lind Centro de Investigación Del Cáncer | Temuco | |
Chile | ONCOCENTRO APYS; Oncología | Vina Del Mar | |
China | Beijing Cancer Hospital | Beijing | |
China | Jilin Cancer Hospital | Changchun | |
China | West China Hospital - Sichuan University | Chengdu City | |
China | Cancer Center of Guangzhou Medical University | Guangzhou | |
China | Sir Run Run Shaw Hospital Zhejiang University | Hangzhou City | |
China | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department | Hangzhou City | |
China | Harbin Medical University Cancer Hospital | Harbin | |
China | Jinan Central Hospital | Jinan City | |
China | Tianjin Cancer Hospital | Tianjin | |
China | Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center | Wuhan | |
China | Henan Cancer Hospital | Zhengzhou | |
Costa Rica | Clinica CIMCA | San José | |
Costa Rica | ICIMED Instituto de Investigación en Ciencias Médicas | San José | |
France | Aphm; Cpcet | Marseille | |
France | Ico Rene Gauducheau; Oncologie | Saint Herblain | |
Greece | General Hospital "G.Papanikolaou"; Pulmonogy Clinic | Asvestochori | |
Greece | Sotiria Hospital | Athens | |
Guatemala | Hospital El Pilar | Ciudad de Guatemala | |
Guatemala | INTEGRA Cancer Institute | Ciudad de Guatemala | |
Guatemala | Oncomedica | Guatemala | |
Guatemala | Grupo Angeles | Guatemala City | |
Hungary | Matrai Gyogyintezet | Matrahaza | |
Hungary | Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz | Székesfehérvár | |
Hungary | Református Pulmonológiai Centrum; Oncology Department | Törökbálint | |
Italy | Asst Papa Giovanni XXIII; Oncologia Medica | Bergamo | Lombardia |
Italy | IRCCS Istituto Clinico Humanitas; Oncologia | Rozzano (MI) | Lombardia |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Centre; Medical Oncology | Seoul | |
Latvia | Riga East Clinical University Hospital Latvian Oncology Centre | Riga | |
Mexico | Health Pharma Professional Research | Cdmx | Mexico CITY (federal District) |
Mexico | Cuidados oncologicos | Querétaro | Queretaro |
New Zealand | Auckland City Hospital, Cancer and Blood Research | Auckland | |
New Zealand | Christchurch Clinical Studies Trust Ltd | Christchurch | |
New Zealand | Waikato Hospital - Cancer and Blood Research Trials Unit; Regional Cancer Centre | Hamilton | |
New Zealand | Tauranga Hospital, Clinical Trials Unit; BOP Clinical School | Tauranga | |
Peru | Centro Medico Monte Carmelo | Arequipa | |
Peru | Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional | Lima | |
Peru | Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel | Lima | |
Peru | Oncosalud Sac; Oncología | Lima | |
Poland | Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Onkologii Klinicznej | Grudzi?dz | |
Poland | Centrum Terapii Wspolczesnej | Lodz | |
Poland | Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology | Otwock | |
Poland | Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz | Warszawa | |
Russian Federation | Chelyabinsk Regional Clinical Oncology Dispensary | Chelyabinsk | Moskovskaja Oblast |
Russian Federation | SBIH Kaluga Region Clinical Oncology Dispensary | Kaluga | |
Russian Federation | FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF | Moscow | Moskovskaja Oblast |
Russian Federation | MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy | Moscow | Moskovskaja Oblast |
Russian Federation | Murmansk Regional Clinical Hospital named after P.A. Bayandin | Murmansk | |
Russian Federation | Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod | Nizhny Novgorod | Niznij Novgorod |
Russian Federation | Multidisciplinary clinic Reaviz | Samara | |
Russian Federation | Mordovia State University | Saransk | Mordovija |
South Africa | Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept | Cape Town | |
South Africa | Wilgers Oncology Centre | Pretoria | |
South Africa | Sandton Oncology Medical Group | Sandton | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario La Paz; Servicio de Oncologia | Madrid | |
Thailand | Chulalongkorn Hospital; Medical Oncology | Bangkok | |
Thailand | Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology | Bangkok | |
Thailand | Rajavithi Hospital; Division of Medical Oncology | Bangkok | |
Thailand | Vajira Hospital | Bangkok | |
Thailand | Prapokklao Hospital | Chanthaburi | |
Thailand | Maharaj Nakorn Chiang Mai Hospital; Department of Medicine | ChiangMai | |
Thailand | Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine | Hat Yai | |
Thailand | Khonkaen Hospital | Khonkaen | |
Thailand | Udonthani Cancer Hospital, Udonthani | Muang,Udonthani | |
Turkey | Ankara Bilkent City Hospital | Ankara | |
Turkey | Kartal Dr Lutfi Kirdar Sehir Hastanesi; Medical Oncology Department | Istanbul | |
Turkey | Medipol University Medical Faculty; Oncology Department | Istanbul | |
Turkey | Ege Uni Medical Faculty Hospital; Oncology Dept | Izmir | |
Turkey | Hacettepe Uni Medical Faculty Hospital; Oncology Dept | Sihhiye/Ankara | |
Ukraine | Municipal Institution City Clinical Hospital #4 of Dnipro City Council | Dnipropetrovsk | Katerynoslav Governorate |
Ukraine | Ivano-Frankivsk Regional Oncology Center | Ivano-Frankivsk | |
Ukraine | Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs | Kharkiv | Kharkiv Governorate |
Ukraine | RCI Sumy Regional Clinical Oncological Dispensary | Sumy | |
United Kingdom | Birmingham Heartlands Hospital | Birmingham | |
United Kingdom | St James Hospital; Dept of Oncology/Hematology | Leeds |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
Argentina, Brazil, Chile, China, Costa Rica, France, Greece, Guatemala, Hungary, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, Russian Federation, South Africa, Spain, Thailand, Turkey, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 | Pre-dose on Day 1 of Cycle 2 (Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2) | ||
Primary | Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1 | Predose on Day 1 of Cycle 2 (Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2) | ||
Primary | Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1 | From start of dosing up to Day 21 in Cycle 1 (Cycle length= 21 days) | ||
Secondary | Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab | Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2) | ||
Secondary | Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab | Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2) | ||
Secondary | Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab | Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2) | ||
Secondary | Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration | Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2. Day=D; Cycle=C. | Cohort 1: Pre&postdose:D1 &postdose: D3,8 of C1; Cohort 2: Pre&postdose: D1 of C1,3 & postdose: D3,8 of C1, Predose: D1 of C2; Cohort 3: Pre& postdose: D1 of C1,2 & postdose: D3,8 of C1, D2,4& 9 of C2& pre dose:D1 of C3 | |
Secondary | Part 1: Percentage of Participants With Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). | Baseline up to data cutoff date for primary analysis, April 26, 2022 (up to approximately 17 months) | |
Secondary | Part 2: Percentage of Participants With AEs | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). | From signing of informed consent form (ICF) until 30 days after last dose of study drug administration in Part 2 (Up to approximately 72 months) | |
Secondary | Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1 | Cycle 1 (Cycle length=21 days) | ||
Secondary | Part 2: Model Predicted Ctrough at Steady State (Cthrough,ss) of Atezolizumab | 1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo. | Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months) | |
Secondary | Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab | 1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo | Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months) | |
Secondary | Part 2: Objective Response Rate (ORR) | ORR is defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to < 10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters in the absence of CR. | From treatment initiation until disease progression or loss of clinical benefit (Up to approximately 72 months). | |
Secondary | Part 2: Progression-Free Survival (PFS) | PFS is defined as the time from study start to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or or death from any cause (whichever occurs first). | From study start to the first occurrence of disease progression or death from any cause, whichever occurs first (Up to approximately 72 months). | |
Secondary | Part 2: Overall Survival (OS) | OS defined as the time from study entry to death from any cause. | From study start to death from any cause (Up to approximately 72 months) | |
Secondary | Part 2: Duration of Response (DOR) | DOR is defined as the time from first occurrence of a documented objective response to disease progression as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. Objective response is defined as the percentage of participants having a CR or PR as determined by investigator assessment of radiographic disease per RECIST v1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the Baseline sum diameters in the absence of CR. | From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 72 months) | |
Secondary | Part 2: Functioning and Global Health Status Over Time, as Assessed by European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)57 | EORTC IL57 questionnaire has10 items and covers 3 scales: physical functioning (PF), role functioning (RF) & global health status/quality of life (GHS/QoL) & 1 item from EORTC Item Library. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks & short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work & pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health & QoL in previous week. Questions are answered on a 4-point Likert scale (where 1="Not at all" to 4="Very much") for physical and role functioning & a 7-point scale (where 1="Very poor" to 7="Excellent") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score. Higher score = better outcome. | From Day 1 of Cycles 1-6 and then every other cycle up to treatment discontinuation visit (Up to approximately 72 months) | |
Secondary | Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ) | Modified SWT scale of the CTSQ consist of seven items that measures seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score Higher scores are associated with higher satisfaction. | Day 1 Cycle 3 or at treatment discontinuation visit (Up to approximately 72 months) | |
Secondary | Part 2: Overall Patient-reported AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 | The overall patient-reported AE burden was assessed using the a single item from the EORTC IL57 questionnaire i.e To what extent have you been troubled with side-effects from your treatment?. The questions is answered on a 4-point Likert scale where 1="Not at all" to 4="Very much". Higher scores indicates greater AE burden. | Day 1 of Cycles 1-6 and then every other cycle up to treatment discontinuation visit (Up to approximately 72 months) | |
Secondary | Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration | From first dose of atezolizumab up to treatment discontinuation visit (Up to approximately 72 Months). | ||
Secondary | Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration Relative to the Prevalence of ADAs at Baseline | From first dose of atezolizumab up to treatment discontinuation visit (Up to approximately 72 Months) | ||
Secondary | Part 2: Convenience, Potential Time Savings, and Overall Satisfaction With Atezolizumab SC Compared With Atezolizumab IV as Assessed by the Health Care Professional (HCP) SC Versus IV Perspective Questionnaire | The HCP Subcutaneous Versus IV Perspective Questionnaire consists of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. | After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 72 months) | |
Secondary | Part 2: Convenience, Ease of Administration, and Overall Satisfaction With Atezolizumab SC Assessed Using HCP Subcutaneous Perspective Questionnaire | The HCP Subcutaneous Perspective Questionnaire consists of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. | After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 72 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |